Anna R. Renzetti , Marco Criscuoli , Aldo Salimbeni , Alessandro Subissi
{"title":"新型非肽血管紧张素AT1受体拮抗剂LR-B/081的分子药理学研究","authors":"Anna R. Renzetti , Marco Criscuoli , Aldo Salimbeni , Alessandro Subissi","doi":"10.1016/0922-4106(95)90028-4","DOIUrl":null,"url":null,"abstract":"<div><p>This report describes the molecular pharmacological properties of LR-B/081 (methyl 2-[[4-butyl-2-methyl-6-oxo-5-[ [2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-1 (6H)-pyrimidinyl]methyl]-3-thiophenecarboxilate), a novel non-peptide angiotensin II receptor antagonist. This compound potently displaced [<sup>3</sup>H]angiotensin II from angiotensin AT<sub>1</sub> (<em>K</em><sub>i</sub> = 1.4 nM, rat adrenal cortex), but not from angiotensin AT<sub>2</sub> (<em>K</em><sub>i</sub> > 1 <em>ω</em>M, bovine cerebellar cortex) receptors and did not show affinity for other receptor systems (<em>K</em><sub>i</sub> > 10 <em>ω</em>M). In saturation studies, LR-B/081 both increased <em>K</em><sub><em>D</em></sub> and decreased <em>B</em><sub><em>max</em></sub> values in a dose-dependent fashion. The rate of dissociation of [<sup>3</sup>H]angiotenin II from angiotensin AT<sub>1</sub> receptors was not affected by the presence of 1 ωM LR-B/081 and the association rate of [<sup>3</sup>H]angiotensin II was not decreased by the presence of 1 or 30 nM LR-B/081, indicating that the <em>B</em><sub>max</sub> reduction was not due to an allosteric interaction or to a delay in reaching the steady-state conditions. These data underline the complexity of the antagonistic nature of LR-B/081, presenting features of both competitive and noncompetitive antagonism.</p></div>","PeriodicalId":100502,"journal":{"name":"European Journal of Pharmacology: Molecular Pharmacology","volume":"290 2","pages":"Pages 151-156"},"PeriodicalIF":0.0000,"publicationDate":"1995-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0922-4106(95)90028-4","citationCount":"6","resultStr":"{\"title\":\"Molecular pharmacology of LR-B/081, a new non-peptide angiotensin AT1 receptor antagonist\",\"authors\":\"Anna R. Renzetti , Marco Criscuoli , Aldo Salimbeni , Alessandro Subissi\",\"doi\":\"10.1016/0922-4106(95)90028-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This report describes the molecular pharmacological properties of LR-B/081 (methyl 2-[[4-butyl-2-methyl-6-oxo-5-[ [2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-1 (6H)-pyrimidinyl]methyl]-3-thiophenecarboxilate), a novel non-peptide angiotensin II receptor antagonist. This compound potently displaced [<sup>3</sup>H]angiotensin II from angiotensin AT<sub>1</sub> (<em>K</em><sub>i</sub> = 1.4 nM, rat adrenal cortex), but not from angiotensin AT<sub>2</sub> (<em>K</em><sub>i</sub> > 1 <em>ω</em>M, bovine cerebellar cortex) receptors and did not show affinity for other receptor systems (<em>K</em><sub>i</sub> > 10 <em>ω</em>M). In saturation studies, LR-B/081 both increased <em>K</em><sub><em>D</em></sub> and decreased <em>B</em><sub><em>max</em></sub> values in a dose-dependent fashion. The rate of dissociation of [<sup>3</sup>H]angiotenin II from angiotensin AT<sub>1</sub> receptors was not affected by the presence of 1 ωM LR-B/081 and the association rate of [<sup>3</sup>H]angiotensin II was not decreased by the presence of 1 or 30 nM LR-B/081, indicating that the <em>B</em><sub>max</sub> reduction was not due to an allosteric interaction or to a delay in reaching the steady-state conditions. These data underline the complexity of the antagonistic nature of LR-B/081, presenting features of both competitive and noncompetitive antagonism.</p></div>\",\"PeriodicalId\":100502,\"journal\":{\"name\":\"European Journal of Pharmacology: Molecular Pharmacology\",\"volume\":\"290 2\",\"pages\":\"Pages 151-156\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1995-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0922-4106(95)90028-4\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmacology: Molecular Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0922410695900284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmacology: Molecular Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0922410695900284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Molecular pharmacology of LR-B/081, a new non-peptide angiotensin AT1 receptor antagonist
This report describes the molecular pharmacological properties of LR-B/081 (methyl 2-[[4-butyl-2-methyl-6-oxo-5-[ [2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-1 (6H)-pyrimidinyl]methyl]-3-thiophenecarboxilate), a novel non-peptide angiotensin II receptor antagonist. This compound potently displaced [3H]angiotensin II from angiotensin AT1 (Ki = 1.4 nM, rat adrenal cortex), but not from angiotensin AT2 (Ki > 1 ωM, bovine cerebellar cortex) receptors and did not show affinity for other receptor systems (Ki > 10 ωM). In saturation studies, LR-B/081 both increased KD and decreased Bmax values in a dose-dependent fashion. The rate of dissociation of [3H]angiotenin II from angiotensin AT1 receptors was not affected by the presence of 1 ωM LR-B/081 and the association rate of [3H]angiotensin II was not decreased by the presence of 1 or 30 nM LR-B/081, indicating that the Bmax reduction was not due to an allosteric interaction or to a delay in reaching the steady-state conditions. These data underline the complexity of the antagonistic nature of LR-B/081, presenting features of both competitive and noncompetitive antagonism.